(Level of Evidence: C) modified (changed time period to be concordant with 2011 PCI guideline75 and replaced clopidogrel and prasugrel with P2Y12 receptor inhibitor ). Class III: No Benefit 1. Dipyridamole is not recommended as an antiplatelet agent in post-UA/NSTEMI patients because it has not been shown to be effective.90,139,140 (Level of Evidence: B) 2011 recommendation remains current. *For aspirin-allergic patients, use either clopidogrel or ticagrelor alone (indefinitely) or try aspirin desensitization. Note that there are no data for therapy with 2 concurrent P2Y12 receptor inhibitors, and this is not recommended in the case of aspirin allergy. The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily.11 Ticagrelor s benefits were observed irrespective of prior therapy with clopidogrel.9 When possible, discontinue ticagrelor at least 5 d before any surgery.12 Issues of patient compliance may be especially important. Consideration should be given to the potential and as yet undetermined risk of intracranial hemorrhage in patients with prior stroke or TIA. Patients weighing 60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily maintenance dose. Consideration should be given to lowering the maintenance dose to 5 mg in patients who weigh 60 kg, although the effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients, a daily maintenance dose should be given for at least 12 mo for patients receiving DES and up to 12 mo for patients receiving BMS unless the risk of bleeding outweighs the anticipated net benefit afforded by a P2Y12 receptor inhibitor. Do not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. 